Valaris Ltd. Form 8-K Summary: Business Combination with Transocean
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 10, 2026, reports on events occurring on February 9, 2026. Valaris Limited (Valaris) and Transocean Ltd. (Transocean) have entered into a definitive Business Combination Agreement. The transaction will be effected via a court-approved scheme of arrangement under Bermuda law, resulting in Valaris becoming a subsidiary of Transocean.
Key Financial Metrics and Transaction Terms
The filing details the terms of the merger rather than historical financial performance metrics such as revenue or cash flow.
- Exchange Ratio: Valaris shareholders will receive 15.235 Transocean Shares for each Valaris Share.
- Ownership Structure: Post-closing, existing Transocean shareholders will own approximately 53% of the combined company, while existing Valaris shareholders will own approximately 47%.
- Termination Fees:
- If Transocean terminates for specific reasons (e.g., Valaris Adverse Recommendation Change), Transocean pays Valaris $195 million.
- If Valaris terminates for specific reasons (e.g., Transocean Adverse Recommendation Change), Valaris pays Transocean $173 million.
- Reimbursement fees for failure to obtain shareholder approval: Up to $65 million (payable by Transocean) or $58 million (payable by Valaris).
- Equity Awards: Outstanding Valaris RSUs and PSUs will vest at the Effective Time and convert into Transocean Shares based on the Exchange Ratio.
- Warrants: Outstanding Valaris Warrants will be assumed by Transocean and adjusted to be exercisable for the Fundamental Transaction Consideration.
Material Changes and Conditions
The primary material change is the entry into the Business Combination Agreement. The transaction is subject to several customary conditions, including:
- Approval by Valaris and Transocean shareholders.
- Sanction of the Scheme of Arrangement by the Supreme Court of Bermuda.
- Listing approval for Transocean shares on the NYSE.
- Receipt of necessary regulatory approvals and expiration of waiting periods.
- Absence of a Material Adverse Effect on either party.
Support Agreements have been signed with shareholders holding approximately 18% of Valaris shares and 9% of Transocean shares, committing them to vote in favor of the transaction.
Outlook, Risks, and Management Commentary
Management has unanimously approved the agreement. The filing includes extensive forward-looking statements regarding the anticipated benefits and timing of the transaction, noting that actual results may differ materially due to various risks.
Key Risks Identified:
- Failure to obtain regulatory or shareholder approvals.
- Disruption to business operations and loss of key personnel or customers during the pendency of the transaction.
- Inability to achieve expected synergies or de-leverage on the expected timeline.
- Market volatility, including oil and gas price fluctuations and global geopolitical conflicts.
- Contractual risks, including counterparties terminating contracts upon a change of control.
The transaction is expected to close on or before February 9, 2027, subject to extensions.
Investor Verification Checklist
- Verify the final Exchange Ratio and any adjustments in the upcoming Joint Proxy Statement.
- Confirm the status of regulatory approvals and the timeline for the Bermuda Supreme Court sanction.
- Review the specific terms regarding the treatment of fractional shares and tax withholding on equity awards.
- Monitor for any "Adverse Recommendation Change" that could trigger termination fees.
- Assess the combined company's debt load and liquidity position once the full proxy statement is filed.